Format

Send to

Choose Destination
Eur J Cancer Clin Oncol. 1986 Mar;22(3):309-12.

A phase II study of tamoxifen in ovarian cancer.

Abstract

A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.

PMID:
3709599
DOI:
10.1016/0277-5379(86)90396-2
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center